NASDAQ:TBRA - Tobira Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$42.09 0.00 (0.00 %)
(As of 07/19/2018 03:46 AM ET)
Previous Close$42.09
Today's Range$42.09 - $42.09
52-Week Range$3.76 - $42.33
Average Volume251,055 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Tobira Therapeutics logoTobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Receive TBRA News and Ratings via Email

Sign-up to receive the latest news and ratings for TBRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A


Debt-to-Equity Ratio0.44
Current Ratio5.38
Quick Ratio5.38


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-153.93%


Outstanding Shares18,820,000
Market Cap$0.00

The Truth About Cryptocurrencies

Tobira Therapeutics (NASDAQ:TBRA) Frequently Asked Questions

What is Tobira Therapeutics' stock symbol?

Tobira Therapeutics trades on the NASDAQ under the ticker symbol "TBRA."

How were Tobira Therapeutics' earnings last quarter?

Tobira Therapeutics Inc (NASDAQ:TBRA) posted its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.08. The biopharmaceutical company earned $1.06 million during the quarter, compared to analyst estimates of $0.15 million. View Tobira Therapeutics' Earnings History.

What is the consensus analysts' recommendation for Tobira Therapeutics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tobira Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Tobira Therapeutics been receiving favorable news coverage?

Headlines about TBRA stock have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tobira Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.34 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Tobira Therapeutics?

Shares of TBRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tobira Therapeutics' stock price today?

One share of TBRA stock can currently be purchased for approximately $42.09.

How can I contact Tobira Therapeutics?

Tobira Therapeutics' mailing address is 701 Gateway Blvd Ste 200, SOUTH SAN FRANCISCO, CA 94080-7041, United States. The biopharmaceutical company can be reached via phone at +1-650-7416625.

MarketBeat Community Rating for Tobira Therapeutics (NASDAQ TBRA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Tobira Therapeutics and other stocks. Vote "Outperform" if you believe TBRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.